| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/CMR.0000000000000103 |
| P8608 | Fatcat ID | release_6djnjdx3hffavcorizwvepcfeq |
| P932 | PMC publication ID | 4384823 |
| P698 | PubMed publication ID | 24950457 |
| P50 | author | Keiran S M Smalley | Q61525717 |
| P2093 | author name string | Bin Fang | |
| Geoffrey T Gibney | |||
| Inna V Fedorenko | |||
| John M Koomen | |||
| P2860 | cites work | MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. | Q37571700 |
| NRAS mutant melanoma: biological behavior and future strategies for therapeutic management | Q37689575 | ||
| Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. | Q39499581 | ||
| ERK and PDE4 cooperate to induce RAF isoform switching in melanoma | Q39561513 | ||
| The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination | Q42726956 | ||
| Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas | Q24303940 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo | Q27852093 | ||
| Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R | Q30425784 | ||
| MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer | Q33443571 | ||
| Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib | Q33758211 | ||
| Evaluating melanoma drug response and therapeutic escape with quantitative proteomics | Q33850665 | ||
| Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases | Q34531564 | ||
| Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. | Q35779541 | ||
| Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 | ||
| RAF265 inhibits the growth of advanced human melanoma tumors | Q37047974 | ||
| Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma | Q37183820 | ||
| In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma | Q37202242 | ||
| Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines | Q37427337 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 448-453 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Melanoma Research | Q6811488 |
| P1476 | title | Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma | |
| P478 | volume | 24 |
| Q38439387 | Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition |
| Q34619118 | Axl as a mediator of cellular growth and survival |
| Q27006853 | Beyond BRAF: where next for melanoma therapy? |
| Q47595971 | Resistance mechanisms to genetic suppression of mutant NRAS in melanoma |
| Q33887664 | Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date |
Search more.